BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22294602)

  • 21. Advanced Techniques for Detection and Identification of Viral Contaminants Using the Ibis PLEX-ID Universal Biosensor.
    Sampath R
    PDA J Pharm Sci Technol; 2011; 65(6):690. PubMed ID: 22294599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contamination by porcine circovirus type 1: findings, investigations, and learnings.
    Piérard I
    PDA J Pharm Sci Technol; 2011; 65(6):614. PubMed ID: 22294584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of a single-platform, rapid, nucleic Acid-based technology for detection of adventitious contaminants of cell culture.
    Dehghani H; Lawrence B; Ill RC
    PDA J Pharm Sci Technol; 2011; 65(6):675-80. PubMed ID: 22294596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory approaches for control of viral contamination of vaccines.
    McClenahan S; Uhlenhaut C; Krause PR
    PDA J Pharm Sci Technol; 2011; 65(6):557-62. PubMed ID: 22294577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Theory and practice of conventional adventitious virus testing.
    Gregersen JP
    PDA J Pharm Sci Technol; 2011; 65(6):634-44. PubMed ID: 22294590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adventitious Agents: Issues and Considerations during Pre-Approval Reviews and Inspections.
    Eltermann J
    PDA J Pharm Sci Technol; 2011; 65(6):694-7. PubMed ID: 22294603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of Latent Retroviruses in Vaccine-related Cell Substrates: Investigation of RT Activity Produced by Chemical Induction of Vero Cells.
    Ma H; Khan AS
    PDA J Pharm Sci Technol; 2011; 65(6):685-9. PubMed ID: 22294598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chlorine dioxide remediation of a virus-contaminated manufacturing facility.
    Lutgen M
    PDA J Pharm Sci Technol; 2011; 65(6):620-4. PubMed ID: 22294587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Practicing safe cell culture: applied process designs for minimizing virus contamination risk.
    Kiss RD
    PDA J Pharm Sci Technol; 2011; 65(6):715-29. PubMed ID: 22294606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of approaches to viral safety issues for biological products.
    Lubiniecki AS
    PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of adventitious viruses from biologicals using a broad-spectrum microbial detection array.
    Jaing C; Gardner S; McLoughlin K; Thissen JB; Slezak T
    PDA J Pharm Sci Technol; 2011; 65(6):668-74. PubMed ID: 22294595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk mitigation strategies for viral contamination of biotechnology products: consideration of best practices.
    Rosenberg AS; Cherney B; Brorson K; Clouse K; Kozlowski S; Hughes P; Friedman R
    PDA J Pharm Sci Technol; 2011; 65(6):563-7. PubMed ID: 22294578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of Risk Assessments in the Design of the Overall Viral Control Strategy Used during the Manufacture and Testing of Live Virus Vaccines.
    Pennathur S
    PDA J Pharm Sci Technol; 2011; 65(6):730-6. PubMed ID: 22294607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adventitious Agent Risk Assessment Case Study: Evaluation of RotaTeq(R) for the Presence of Porcine Circovirus.
    Ranucci CS; Tagmyer T; Duncan P
    PDA J Pharm Sci Technol; 2011; 65(6):589-98. PubMed ID: 22294581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mouse Minute Virus (MMV) Contamination--A Case Study: Detection, Root Cause Determination, and Corrective Actions.
    Moody M; Alves W; Varghese J; Khan F
    PDA J Pharm Sci Technol; 2011; 65(6):580-8. PubMed ID: 22294580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Broadening our expectations for viral safety risk mitigation.
    Kljavin IJ
    PDA J Pharm Sci Technol; 2011; 65(6):645-53. PubMed ID: 22294591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PDA Virus Filter Task Force update.
    Sofer G
    Dev Biol (Basel); 2004; 118():129-31. PubMed ID: 15645682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PDA/FDA Adventitious Agents and Novel Cell Substrates: Emerging Technologies and New Challenges, Nov. 3-4, 2011, Rockville, MD.
    Khan AS; Lubiniecki A; King KE
    PDA J Pharm Sci Technol; 2012; 66(6):502-11. PubMed ID: 23183646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meeting Report: 2015 PDA Virus & TSE Safety Forum.
    Willkommen H; Blümel J; Brorson K; Chen D; Chen Q; Gröner A; Kreil TR; Ruffing M; Ruiz S; Scott D; Silvester G
    PDA J Pharm Sci Technol; 2016; 70(2):177-88. PubMed ID: 27020643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meth task force established.
    AIDS Patient Care STDS; 2005 Jul; 19(7):469-70. PubMed ID: 16053405
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.